NEW YORK (GenomeWeb News) – The plaintiff in a lawsuit that accused Sequenom of capping the price of its MaterniT21 Plus non-invasive prenatal test in order to drive up its adoption has dropped her case.

The plaintiff Bette Borenstein voluntarily dismissed her lawsuit earlier this week in US District Court for the Southern District of California five months after initiating the litigation. No reason was provided in court papers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.